China Pharma Holdings (CPHI) Finished Goods (2017 - 2024)

China Pharma Holdings has reported Finished Goods for 8 years, with the latest figure at $1.3 million in Q3 2024.

• For the quarter ending Q3 2024, Finished Goods rose 6.83% year-over-year to $1.3 million; the trailing twelve-month figure through Sep 2024 stood at $1.3 million (up 6.83% YoY), and the FY2023 full-year result was $1.5 million, up 166.73% from the prior year.
• Finished Goods for Q3 2024 stood at $1.3 million, down from $1.5 million in the prior quarter.
• The five-year high for Finished Goods was $1.7 million in Q1 2024, with the low at $551000.0 in Q4 2021.
• Historically, Finished Goods has averaged $1.2 million across 5 years, with a median of $1.3 million in 2022.
• Annual changes were most pronounced in 2021 — Finished Goods slumped 46.0% — and 2023, when it soared 166.73%.
• China Pharma Holdings' Finished Goods stood at $960375.0 in 2020, then slumped by 42.63% to $551000.0 in 2021, then changed by 0.0% to $551000.0 in 2022, then jumped by 166.73% to $1.5 million in 2023, then slipped by 11.91% to $1.3 million in 2024.
• The last three Finished Goods figures came in at $1.3 million (Q3 2024), $1.5 million (Q2 2024), and $1.7 million (Q1 2024), per Business Quant data.